Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT ID: NCT02006498

Last Updated: 2016-01-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 99 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-06-30
• Study Completion Date: 2015-12-31

Brief Summary

This is a randomised study to examine whether high dose Sillymarin will be able to help improve fat-induced liver damage in the liver. The study hypothesis is that high dose Sillymarin will be able to reduce steato-hepatitis (fat-related liver inflammation) better than placebo.

Detailed Description

OBJECTIVES OF STUDY Primary Objectives

1. To assess the safety and adverse event profile of Silymarin compared to placebo.

2. To assess the efficacy of Silymarin as defined by an improvement in non-alcoholic steatosis (NAS) activity score by at least 30% from baseline compared to placebo.

Secondary Objectives

1. To compare NAS activity before and after Silymarin therapy.

2. To characterize changes in ALT and AST during Silymarin therapy.

3. To compare insulin resistance measured by HOMAr during Silymarin therapy.

Conditions

Non-alcoholic Fatty Liver Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Sillymarin

Active component study medication

Group Type: EXPERIMENTAL

Sillymarin

Intervention Type: DRUG

Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.

Placebo

Placebo capsules

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo capsule with same appearances as study drug

Interventions

Sillymarin

Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.

Intervention Type: DRUG

Placebo

Placebo capsule with same appearances as study drug

Intervention Type: DRUG

Other Intervention Names

Legalon

Eligibility Criteria

Inclusion Criteria

• Male or female 18 years of age or older.
• Diagnosed with NASH (refer to Section 5.2)
• AST and/or ALT greater than 40 IU/L.
• Must agree to adhere to alcohol consumption guideline.
• Weight gain//loss of no more than 10% between biopsy and screening or within 30 days of screening if the biopsy is performed during the screening period.
• No change in diabetic and/or lipid medications between biopsy and screening or within 30 days of screening if the biopsy is performed during the screening period

Exclusion Criteria

• Use of silymarin or other milk thistle preparations for a period of 90 consecutive days or longer between biopsy and initial screening, or within 30 days prior to screening if the biopsy is performed during the screening period.

• Use of other antioxidants or non-prescribed complementary alternative medications for a period of 90 consecutive days or longer between biopsy and initial screening, or within 30 days prior to screening if the biopsy is performed during the screening period.
• Use of warfarin, metronidazole, or acetaminophen (greater than 2 grams per day) between screening and randomization.
• Use of oral steroids for more than 14 days of screening or prior to randomization.
• BMI ≥ 35 kg/m2 between screening and randomization.
• Poorly-controlled diabetes (HbA1c > 8 %) between screening and randomization
• Diabetes mellitus treated with oral agents other than the secretagogues or metformin between screening and randomization. Sitagliptin is allowed.
• For patients using anti-hyperlipidemic agents or accepted anti-diabetic agents, any change of agent or dose between screening and randomization.
• Radiologic imaging consistent with cirrhosis or portal hypertension.
• Evidence of decompensated liver disease
• Platelet count < 130 x 109 /L at screening.
• History of bariatric surgery, or undergoing evaluation for bariatric surgery.
• Known allergy/sensitivity to milk thistle or its preparations.
• History of immunologically mediated disease
• History of thyroid disease poorly controlled on prescribed medications.
• History of solid organ or bone marrow transplantation.
• Primary hepatic malignancy.
• Secondary hepatic malignancy or extrahepatic malignancy.
• Serum Creatinine of 176 μmol/L or greater or creatinine clearance (calculated according to Cockcroft-Gault) 60 mL/min or less, or on dialysis, at screening.
• Severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study.
• Women with ongoing pregnancy or breast feeding, or contemplating pregnancy.
• Women of childbearing potential who are not practicing an acceptable form of birth control.
• Participation in a research drug trial within 30 days of screening.
• Inability or unwillingness to give informed consent or abide by the study protocol.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Rottapharm

INDUSTRY

Sponsor Role: collaborator

University of Malaya

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sanjiv Mahadeva, MD, MRCP

Role: PRINCIPAL_INVESTIGATOR

University of Malaya

Locations

University Malaya Medical Centre

Kuala Lumpur, Kuala Lumpur, Malaysia

Countries

Malaysia

References

Wah Kheong C, Nik Mustapha NR, Mahadeva S. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2017 Dec;15(12):1940-1949.e8. doi: 10.1016/j.cgh.2017.04.016. Epub 2017 Apr 15.

Reference Type: DERIVED

PMID: 28419855 (View on PubMed)

Other Identifiers

LE13T0.01

Identifier Type: -

Identifier Source: org_study_id